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ABSTRACT: We report the crystal structure of the anhydrous
phase of cimetidine hydrochloride, determined directly from
powder X-ray diﬀraction data. The material was prepared by
dehydration of the readily obtained monohydrate form of
cimetidine hydrochloride, the only form for which a crystal
structure has previously been reported. As such, solid-state
dehydration processes typically yield the product phase as a
microcrystalline powder, and structure determination was carried
out directly from powder X-ray diﬀraction data, using the direct-space genetic algorithm technique for structure solution followed
by Rietveld reﬁnement. The structure determined from powder X-ray diﬀraction was further validated by calculating solid-state
13C NMR data for the crystal structure (using ﬁrst-principles periodic DFT techniques within the GIPAW approach) and
assessing the quality of agreement with the corresponding experimental solid-state 13C CPMAS NMR data. This strategy
provides a robust vindication of the correctness of the crystal structure by assessing the quality of agreement of the structure both
with experimental powder X-ray diﬀraction data and with experimental solid-state 13C NMR data.
■ INTRODUCTION
Powder X-ray diﬀraction (XRD) and solid-state NMR spec-
troscopy are two of the most powerful techniques for
characterizing structural properties of polycrystalline samples
of organic materials. Within the context of crystal structure
determination, the prospects for combining the complementary
information provided by these two techniques has the potential
to yield more detailed insights than may be obtained from the
use of just one of these techniques alone. In particular,
determination of a crystal structure directly from powder XRD
data1−9 followed by calculation of solid-state 1H and 13C NMR
chemical shifts [using the GIPAW (Gauge Including Projector
Augmented Wave) approach10−14] for the crystal structure
allows a robust independent veriﬁcation of the correctness of
the structure.15−22 As such, this combined methodology serves
an important role within the wider ﬁeld of NMR Crystallog-
raphy.23−26
The focus of the present study is the structural properties of
the histamine H2 antagonist cimetidine. In pharmaceutical
applications, cimetidine is marketed either as the free base or as
the hydrochloride salt. In common with many pharmaceuticals,
the salt is favored in cases for which rapid dissolution is
desired.27 The free base form of cimetidine has a high
propensity for polymorphism. Based on an FT-IR study,
Hegedüs and Görög28 list a total of four polymorphs of the free
base as well as three distinct monohydrate forms containing the
free base, of which the crystal structures of three
polymorphs29−31 and one monohydrate form32 have been
reported.
In contrast, the crystal structure of the hydrochloride salt of
cimetidine (Figure 1) has never been reported, presumably as a
consequence of the challenge of growing a single crystal of this
material suitable for single-crystal XRD. Furthermore, we note
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Figure 1.Molecular structure of cimetidine hydrochloride showing the
atom numbering scheme. Atoms 1 to 5 (with attached hydrogen
atoms) constitute the imidazolium ring (note that protonation of
cimetidine occurs on the imidazole group). Atoms 10, 11, 12, and 15
(with attached hydrogen atoms) constitute the guanidine moiety.
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that cimetidine hydrochloride has a high propensity to undergo
hydration in an ambient atmosphere to form a monohydrate
phase (the crystal structure of which has been reported33). The
anhydrous phase of cimetidine hydrochloride may be obtained
by solid-state dehydration of the monohydrate phase, although
this procedure yields a microcrystalline powder of the
anhydrous phase.
In the present paper, we exploit powder XRD, combined
with analysis of solid-state NMR data, to determine the crystal
structure of the anhydrous phase of cimetidine hydrochloride.
Although the task of determining crystal structures from
powder XRD data is signiﬁcantly more challenging than from
single-crystal XRD data, particularly in the case of organic
molecular materials, advances over the last 20 years or so in the
techniques for data analysis are such that it is now feasible to
determine the structural properties of organic materials of
moderate complexity directly from powder XRD data.1−9 In
this regard, the direct-space strategy for structure solution has
created considerable opportunities and has become the
standard approach for tackling structure solution of organic
materials from powder XRD data. The prospect of determining
crystal structures directly from powder XRD data provides an
essential opportunity for structural characterization of organic
materials prepared by processes that intrinsically generate
microcrystalline powders as the product phase, including (as in
the present work) those prepared by solid-state dehydration
procedures.
Following determination of the crystal structure of the
anhydrous phase of cimetidine hydrochloride from powder
XRD data in the present work, ﬁrst-principles DFT calculations
within the GIPAW approach were used to calculate the solid-
state 13C NMR data corresponding to the structure, followed
by careful scrutiny of the agreement between the calculated and
experimental solid-state 13C NMR data. The key feature of this
combined strategy is that the quality of the crystal structure
determined from the powder XRD data is assessed both against
the experimental powder XRD data and against the
experimental solid-state NMR data, representing a stringent
and robust assessment of the validity and quality of the crystal
structure.
■ EXPERIMENTAL SECTION
The sample of cimetidine hydrochloride used in this work was
purchased from Sigma-Aldrich. Powder XRD data were recorded at 21
°C on a Bruker D8 instrument (Ge-monochromated CuKα1 radiation)
operating in transmission mode. As cimetidine hydrochloride is
susceptible to hydration (to form the monohydrate phase), the
purchased sample was dried at 100 °C before packing into capillaries
which were then quickly ﬂame-sealed. The capillaries were mounted
on a disk sample holder, and two sets of powder XRD data were
recorded. The ﬁrst data set was recorded over 32 h with 2θ range 4−
50° and step size 0.017°, while the second data set was recorded over
90 h with 2θ range 6−70° and step size 0.017°.
High-resolution solid-state 13C NMR data were recorded at a
magnetic ﬁeld of 11.7 T (13C Larmor frequency, 125.8 MHz) using a
Bruker AVANCE III spectrometer. The sample was used as purchased
and packed inside a standard solid-state NMR rotor. The spectra were
acquired at ambient temperature using ramped 1H → 13C cross-
polarization34 (CP) with a contact time of 1 ms, magic-angle spinning
(MAS; spinning frequency, 12.5 kHz), and 1H decoupling using the
SPINAL-64 sequence.35 The 1H nutation frequency for both the 90°
pulse and decoupling was 100 kHz. The recycle delay was 3 s and 256
transients were added. The 13C NMR spectra were referenced against
L-alanine, with the carboxylate resonance set to 177.8 ppm,
corresponding to tetramethylsilane (TMS) as the primary reference.
Structure Determination. The two sets of powder XRD data
diﬀered in that the ﬁrst, recorded over the 2θ range 4−50°, had a
lower signal-to-noise ratio, but did not contain any contamination
from the monohydrate phase of cimetidine hydrochloride. On the
other hand, the second set of powder XRD data, which was recorded
over the more extended 2θ range 6−70°, contained some peaks from
the monohydrate phase (due to a small amount of water penetrating
the capillary during the period of several months between the two
measurements). The ﬁrst data set was used for indexing and structure
solution (beneﬁting from the fact that this data set was recorded for a
monophasic sample of anhydrous cimetidine hydrochloride) whereas
the second data set was used for the ﬁnal Rietveld reﬁnement
(beneﬁting from the fact that this data set extends to a signiﬁcantly
higher maximum value of 2θ), with the monohydrate structure added
as a “second phase” in the reﬁnement calculations.
The powder XRD pattern of cimetidine hydrochloride was indexed
using the DICVOL91 algorithm36 in the CRYSFIRE program,37 giving
the following unit cell with monoclinic metric symmetry: a = 13.63 Å,
b = 7.66 Å, c = 14.44 Å, β = 108.3°. On the basis of density
considerations, the number of formula units in the unit cell was
deduced to be Z = 4. Proﬁle ﬁtting using the Le Bail technique38 in the
program GSAS39 could not distinguish unambiguously between several
of the primitive monoclinic space groups and independent structure-
solution calculations were carried out for nine space groups in this
category. The results indicated that P21/a is the correct space group.
Le Bail ﬁtting for this space group gave a good ﬁt (Rwp = 1.65%, Rp =
1.26%) to the powder XRD data (at this stage, using the powder XRD
data set recorded over the 2θ range 4−50°).
Structure solution was carried out using the direct-space genetic
algorithm (GA) technique40−42 incorporated in the program
EAGER.43−49 In the GA structure-solution calculation, the cimetidi-
nium cation was deﬁned by a total of 15 structural variables (3
positional, 3 orientational, and 9 torsional). The chloride anion was
deﬁned by 3 positional variables. Each GA structure-solution
calculation involved the evolution of 500 generations for a population
of 200 structures, with 20 mating operations and 100 mutation
operations carried out per generation. For space group P21/a, a total of
16 independent calculations were carried out, with the same good-
quality structure solution obtained in 9 cases.
The best structure solution (i.e., the trial structure with lowest Rwp
obtained in the GA calculations) was used as the initial structural
model for Rietveld reﬁnement,50,51 which was carried out using the
GSAS program. Standard restraints were applied to bond lengths and
bond angles52 and planar restraints were applied to the imidazolium
ring and the guanidine moiety. A common isotropic displacement
parameter was reﬁned for the non-hydrogen atoms of the
cimetidinium cation and a separate isotropic displacement parameter
was reﬁned for the chloride anion. No correction for preferred
orientation was required. The ﬁnal Rietveld reﬁnement was carried out
using the data set recorded over the 2θ range 6−70°, with cimetidine
hydrochloride monohydrate included as a second phase in the
reﬁnement. Le Bail ﬁtting of this set of powder XRD data gave a good
ﬁt (Rwp = 1.11%, Rp = 0.82%; Figure 2). The quality of ﬁt obtained in
the ﬁnal Rietveld reﬁnement (Rwp = 1.38%, Rp = 1.01%; Figure 3) was
acceptably close to that obtained in the Le Bail ﬁtting procedure on
the same data set. From the reﬁned relative scale factor, the proportion
of the monohydrate phase in the sample was estimated to be ca. 15%.
Final reﬁned parameters for cimetidine hydrochloride: a = 13.6020(6)
Å, b = 7.65886(27) Å, c = 14.4257(5) Å, β = 108.3724(18)°, V =
1425.21(14) Å3 (2θ range, 6−70°; 3868 proﬁle points; 141 reﬁned
variables).
DFT Calculations. The NMR chemical shifts for the crystal
structure of anhydrous cimetidine hydrochloride were calculated using
the CASTEP program53 (Academic Release version 8.0). First, the
crystal structure was subjected to geometry optimization, using a basis
set cutoﬀ energy of 700 eV, ultrasoft pseudopotentials,54 PBE
functional,55 semiempirical dispersion corrections (TS correction
scheme56), ﬁxed unit cell, preserved space group symmetry and
periodic boundary conditions. CASTEP was then used to calculate the
chemical shifts, using the GIPAW approach,10−14 with a cutoﬀ energy
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of 700 eV. Both calculations used a Monkhorst−Pack grid57 of
minimum sample spacing 0.05 × 2π Å−1, for which both types of
calculation were found to have converged. Referencing of the 13C
chemical shifts was achieved using the formula δiso(calc) =
σref − σiso(calc), where σref was determined by adding the mean of
the calculated shielding values to the mean of the experimental
chemical shifts.12 For our calculated and experimental values, this
calculation led to a reference value σref = 173.8 ppm. This method of
referencing does not require assignment of the peaks except when two
peaks overlap, which occurs in the present case for C2 and C4, and for
C8 and C16. Additional GIPAW calculations on the anhydrous form
of cimetidine hydrochloride and the monohydrate form of cimetidine
hydrochloride33 are included in Supporting Information. The results
from these calculations conﬁrm that the sample analyzed in our
experimental solid-state 13C NMR study was indeed the anhydrous
form of cimetidine hydrochloride.
■ RESULTS AND DISCUSSION
The ﬁnal reﬁned crystal structure of cimetidine hydrochloride is
shown in Figure 4, viewed along the a-axis. The structure may
be described in terms of slabs parallel to the ab-plane, with each
slab constructed from the interdigitation of two complementary
layers (the two layers are highlighted by yellow and blue
shading in Figure 4). Within a single layer (Figure 5), the
methylimidazolium moiety of the cimetidinium cation and the
chloride anions lie parallel the ab-plane and form a zigzag
hydrogen-bonded chain that runs parallel to the a-axis. This
zigzag hydrogen-bonded chain is constructed from the N−H···
Cl−···H−N motif, involving N−H bonds from the methyl-
imidazolium moieties (i.e., N1 and N3) of two adjacent
cimetidinium cations as the donors and an intervening chloride
anion as the acceptor. The methylcyanoguanidine parts of the
molecule protrude perpendicular to the ab-plane and it is these
parts of the molecule that are involved in the interdigitation of
complementary layers. Within a given layer, a second type of
hydrogen-bonded chain runs along the a-axis (Figure 6),
speciﬁcally a linear array of intermolecular N−H···N hydrogen
bonds involving the methylcyanoguanidine parts of adjacent
molecules (with N15−H as the donor and N14 as the
acceptor). We note that one N−H bond (N10) of the
guanidine moiety is not engaged in any hydrogen bonding, and
the distance to the nearest potential hydrogen-bond acceptor
(the S atom of a neighboring molecule) is 4.17 Å.
From the above discussion, it is clear that hydrogen bonding
exists only within each layer (see Figures 5 and 6). There is no
hydrogen bonding between the two layers that interdigitate
with each other to construct a given slab, and there is no
hydrogen bonding between adjacent slabs. The interface
between adjacent slabs involves the two-dimensional hydro-
gen-bonded arrays of methylimidazolium moieties and chloride
anions that lie parallel to the ab-plane. At this interface, the
two-dimensional arrays in adjacent slabs are related to each
other by an inversion center, which generates an oﬀset between
the positions of like charges in the two arrays. Consequently,
the shortest Cl−···Cl− distance at the interface between adjacent
slabs is 4.93 Å.
The hydrogen-bonding pattern in the anhydrous form of
cimetidine hydrochloride reported here is signiﬁcantly diﬀerent
from that in the monohydrate form.33 The monohydrate
contains N3−H···N14 hydrogen bonds between cimetidinium
cations together with N12···H−O and N15−H···O hydrogen
bonds between cimetidinium cations and water molecules. In
addition, the chloride anion is engaged in an O−H···Cl−
hydrogen bond involving the water molecule as the donor,
and in N−H···Cl− hydrogen bonds involving N10 and N1 of
the cimetidinium cation as N−H donors. Consequently, all four
N−H hydrogen bond donors in the cimetidinium cation are
engaged in hydrogen bonding. In contrast, for the anhydrous
phase, only three of the four potential N−H donors are
involved in hydrogen bonding.
The cimetidinium cation has a signiﬁcantly diﬀerent
conformation in the crystal structures of the anhydrous and
monohydrate phases, as evident from the overlay plots in
Figure 7. The key conformational diﬀerence between the two
structures arises around C8, while the moieties at each end of
the molecule share very similar conformational characteristics
in the anhydrous and monohydrate crystal structures. We note
that the substantial diﬀerence in molecular conformation
between the monohydrate phase and the anhydrous phase
Figure 2. Le Bail ﬁt of the powder XRD pattern (with background
subtracted) of anhydrous cimetidine hydrochloride (red + marks,
experimental data; green line, calculated data; magenta line, diﬀerence
plot; black tick marks, predicted peak positions). The blue tick marks
represent cimetidine hydrochloride monohydrate, which was added as
a second phase in the Le Bail ﬁtting.
Figure 3. Rietveld reﬁnement for anhydrous cimetidine hydrochloride
(red + marks, experimental data; green line, calculated data; magenta
line, diﬀerence plot; black tick marks, predicted peak positions). The
background of the powder XRD pattern has been subtracted. The blue
tick marks represent cimetidine hydrochloride monohydrate, which
was added as a second phase in the Rietveld reﬁnement.
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may be a signiﬁcant factor contributing to the fact that
dehydration of the monohydrate phase occurs with loss of
crystallinity, resulting in a microcrystalline powder sample of
the anhydrous phase.
To provide robust validation58 of the crystal structure of
anhydrous cimetidine hydrochloride determined here from
powder XRD data, geometry optimization was carried out using
periodic DFT calculations (with ﬁxed unit cell parameters)
using the program CASTEP. The optimized structure is very
close to that determined from powder XRD data. The
maximum displacement for any of the non-hydrogen atoms is
Figure 4. Crystal structure of anhydrous cimetidine hydrochloride viewed along the a-axis. The structure is described in terms of slabs parallel to the
ab-plane, with each slab constructed from two interdigitated layers. In the ﬁgure, two layers that interdigitate to form a single slab are indicated by
yellow shading and blue shading. Hydrogen bonds are indicated by green dashed lines. Hydrogen bonding exists only within each layer (see Figures
5 and 6 for more details). There is no hydrogen bonding between the two layers that construct a given slab, and there is no hydrogen bonding
between adjacent slabs.
Figure 5. Crystal structure of anhydrous cimetidine hydrochloride
showing a single hydrogen-bonded layer parallel to the ab-plane.
Hydrogen bonds are indicated by green dashed lines. The zigzag
hydrogen-bonded chains running along the a-axis, constructed from
the N−H···Cl−···H−N motif (involving two N−H bonds of each
methylimidazolium moiety and the chloride anions) are clearly
evident.
Figure 6. Linear hydrogen-bonded chains (constructed from N−H···N
interactions between cimetidinium cations) that run along the a-axis in
the crystal structure of anhydrous cimetidine hydrochloride. Hydrogen
bonds are indicated by green dashed lines.
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only 0.15 Å (the largest displacements are for C9 and N10) and
the mean atomic displacement is 0.09 Å. For the hydrogen
atoms, the largest displacement is 0.18 Å for one of the
hydrogen atoms in the C8 methylene group. Such close
agreement between the structure determined from powder
XRD data and the structure obtained following geometry
optimization with periodic DFT indicates clearly that the
structure determined from powder XRD data is very close to a
minimum on the global energy landscape for this molecule with
the given unit cell parameters and space group.
To provide additional scrutiny of the correctness of the
crystal structure, the isotropic 13C chemical shifts were
calculated using the program CASTEP (employing the
GIPAW approach10−14). In Table 1, the calculated isotropic
13C chemical shifts are compared with those in the experimental
high-resolution solid-state 13C NMR spectrum recorded at 11.7
T. Figure 8 shows the experimental 1H → 13C CPMAS NMR
spectrum of cimetidine hydrochloride together with the peak
positions calculated from the DFT calculation. Although there
are some small diﬀerences, the overall agreement is good and
each calculated peak is within 3.8 ppm of the corresponding
experimental peak. The largest discrepancies are for C6 (the
carbon atom between the imidazolium ring and the sulfur
atom) and C11 (the central carbon in the guanidine moiety).
The isotropic 13C NMR chemical shifts calculated for the
crystal structure of cimetidine hydrochloride monohydrate (see
Supporting Information) show signiﬁcant diﬀerences from
those observed in the experimental solid-state 13C NMR
spectrum reported here (particularly for C6, C8, C11, and
C13), conﬁrming that the sample used for our solid-state 13C
NMR measurement was indeed the anhydrous form of
cimetidine hydrochloride. Such large diﬀerences are not
surprising given the distinctly diﬀerent conformations adopted
by the cimetidinium cation in the two crystal structures. We
note that close inspection of our solid-state 13C NMR spectrum
for the anhydrous form reveals a weak peak at 120 ppm which
could potentially be due to a small impurity amount of the
monohydrate phase.
■ CONCLUDING REMARKS
The crystal structure of anhydrous cimetidine hydrochloride
has been determined by taking advantage of the opportunities
that now exist for structure determination of organic materials
directly from powder XRD data. As cimetidine hydrochloride
has a high propensity to undergo hydration in an ambient
atmosphere, preparation of the anhydrous phase by a solid-state
dehydration procedure meant that only a microcrystalline
powder sample was available, necessitating the use of powder
XRD data for structure determination. Geometry optimization
using periodic DFT calculations and computation of isotropic
solid-state 13C NMR chemical shifts for comparison with
experimental values provide robust independent veriﬁcation of
the correctness of this structure. While this combined approach
involving powder XRD and solid-state NMR has been used
previously in structure determination of materials composed of
a single type of molecule15−18 or neutral cocrystals,19−22 the
present work represents the ﬁrst application of this combined
methodology in the case of an organic salt. As such materials
are common in pharmaceutical applications, we anticipate that
this combined powder XRD/solid-state NMR approach will be
used extensively in the future in the structural characterization
of pharmaceutical materials.
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Figure 7. Overlays of the cimetidinium cations in the crystal structures
of anhydrous cimetidine hydrochloride (magenta) and cimetidine
hydrochloride monohydrate (cyan). In (a) the methylimidazolium
moieties are superimposed whereas in (b) the methylcyanoguanidine
moieties are superimposed. In each case, the C8 atoms are ringed.
Table 1. Calculated (GIPAW) Values of the Isotropic 13C
NMR Chemical Shifts [δiso(calc)] and Experimental Values
of the Isotropic 13C NMR Chemical Shifts [δiso(exp)] for
Cimetidine Hydrochloride
Site δiso(calc)/ppm δiso(exp)/ppm δiso(exp) − δiso(calc)
C2 133.0 133.3 0.3
C4 133.8 133.3 −0.5
C5 129.5 128.7 −0.8
C6 26.8 23.0 −3.8
C7 9.4 10.3 0.9
C8 30.6 28.6 −2.0
C9 43.1 42.3 −0.7
C11 157.4 160.9 3.5
C13 123.3 126.1 2.8
C16 28.3 28.6 0.3
Figure 8. Experimental 1H (500 MHz) →13C CPMAS (12.5 kHz)
NMR spectrum of anhydrous cimetidine hydrochloride. The peak
positions calculated for the crystal structure using the GIPAW method
are shown below the spectrum (diﬀerent colors are used simply to
distinguish calculated peaks that are in close proximity to each other).
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Supporting Information contains tables and a ﬁgure
comparing calculated and experimental solid-state 13C
NMR chemical shifts (PDF)
Information on the experimental data that supports the
results presented in this paper, including the magres
output (.magres) ﬁles from the CASTEP calculations
(containing the magnetic shielding and electric ﬁeld
gradient parameters for all atoms in the crystal structure),
together with instructions on how to access this
information, can be found in the Cardiﬀ University
data catalogue at http://dx.doi.org/10.17035/d.2016.
0008378127
Accession Codes
CCDC 1445765 contains the supplementary crystallographic
data for this paper. These data can be obtained free of charge
via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_
request@ccdc.cam.ac.uk, or by contacting The Cambridge
Crystallographic Data Centre, 12, Union Road, Cambridge
CB2 1EZ, UK; fax: +44 1223 336033.
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